A multi-center, double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of 14-day inhaled TPI ASM8 in subjects with asthma.
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2012
At a glance
- Drugs ASM 8 (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2012 Company added in association field as reported by ClinicalTrials.gov.
- 14 Dec 2008 Trial end date changed from 1 Jul 2008 to 1 Oct 2008 as reported by Clinicaltrials.gov.
- 14 Dec 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.